A milestone for liquid biopsy
The FDA approved the first-ever test that can detect multiple types of cancer from a blood sample, something previously only possible by extracting tissue.
As STAT’s Elizabeth Cooney reports, the test, made by Foundation Medicine, scans blood for the telltale genetic signatures of cancer to both identify specific subtypes of the disease and and match patients to targeted therapies. Similar blood tests, called liquid biopsies, have been approved for individual tumor types, but Foundation’s is the first pan-cancer assay.
The challenge facing the nascent liquid biopsy industry — which includes Foundation, Thrive, Grail, and Guardant — is demonstrating that its products can find more mutations than a standard tissue biopsy can, something that will take more research to prove.
Read more.
As STAT’s Elizabeth Cooney reports, the test, made by Foundation Medicine, scans blood for the telltale genetic signatures of cancer to both identify specific subtypes of the disease and and match patients to targeted therapies. Similar blood tests, called liquid biopsies, have been approved for individual tumor types, but Foundation’s is the first pan-cancer assay.
The challenge facing the nascent liquid biopsy industry — which includes Foundation, Thrive, Grail, and Guardant — is demonstrating that its products can find more mutations than a standard tissue biopsy can, something that will take more research to prove.
Read more.
.png)
No hay comentarios:
Publicar un comentario